ReferIndia News Granules India US Subsidiary Receives FDA EIR with No Action Indicated Status

ReferIndia News

Mumbai’s Trusted Investment Experts

24+ years of financial planning, portfolio management & wealth growth.

Learn More
News Image

Granules India US Subsidiary Receives FDA EIR with No Action Indicated Status

Published on: March 5, 2026, 11:46 a.m. | Source: scanx.trade

Granules India's US subsidiary Granules Consumer Health has received an FDA Establishment Inspection Report with No Action Indicated status following a December 2025 inspection of its Manassas, Virginia packaging facility. This marks the second consecutive clean FDA audit with zero observations, demonstrating the facility's strong regulatory compliance in processing controlled substances and OTC products across three packaging lines.

Checkout more news
Ad Banner

✅ Secure, cloud-based clinic management software

Manage digital prescriptions, appointments, patient records, billing, files, and reports — everything your clinic needs in one powerful platform.

Know more
ReferIndia News contact